Do we still need lead-in dosing of Nevirapine in HIV-infected patients who are receiving rifampicin-containing antituberculous therapy?
Journal
Clinical Infectious Diseases
Journal Volume
49
Journal Issue
9
Pages
1452-1453
Date Issued
2009
Author(s)
SDGs
Other Subjects
efavirenz; nevirapine; rifampicin; drug blood level; human; Human immunodeficiency virus infected patient; Human immunodeficiency virus infection; letter; priority journal; tuberculosis; vertical transmission; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Interactions; Female; HIV Infections; Humans; Male; Middle Aged; Nevirapine; Reverse Transcriptase Inhibitors; Rifampin; Treatment Outcome; Tuberculosis
Type
letter